Karyopharm Therapeutics (NASDAQ:KPTI) Cut to Neutral at Rodman & Renshaw

Rodman & Renshaw downgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a buy rating to a neutral rating in a research report report published on Monday, Marketbeat Ratings reports.

KPTI has been the subject of several other reports. Piper Sandler cut their target price on shares of Karyopharm Therapeutics to $7.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Wall Street Zen downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. HC Wainwright lowered Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a research note on Friday, July 31st. Weiss Ratings lowered Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 24th. Finally, Robert W. Baird cut Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research report on Friday, July 31st. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $11.50.

Karyopharm Therapeutics Trading Down 7.9%

NASDAQ KPTI opened at $0.08 on Monday. The firm’s fifty day moving average price is $1.11 and its two-hundred day moving average price is $5.91. Karyopharm Therapeutics has a 1 year low of $0.07 and a 1 year high of $10.99. The firm has a market capitalization of $1.84 million, a P/E ratio of -0.01 and a beta of 1.16.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($2.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.95). The business had revenue of $33.43 million for the quarter, compared to analysts’ expectations of $32.19 million. On average, research analysts anticipate that Karyopharm Therapeutics will post -4.70 EPS for the current fiscal year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Several large investors have recently modified their holdings of the stock. Commodore Capital LP bought a new position in Karyopharm Therapeutics in the 1st quarter valued at about $10,862,000. Avidity Partners Management LP lifted its position in Karyopharm Therapeutics by 244.6% during the first quarter. Avidity Partners Management LP now owns 463,741 shares of the company’s stock worth $2,583,000 after acquiring an additional 329,175 shares during the last quarter. Context Capital Management LLC acquired a new stake in Karyopharm Therapeutics during the third quarter worth approximately $322,000. Squarepoint Ops LLC acquired a new stake in Karyopharm Therapeutics during the second quarter worth approximately $623,000. Finally, Headlands Technologies LLC bought a new stake in shares of Karyopharm Therapeutics during the second quarter worth approximately $118,000. 66.44% of the stock is owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company’s research centers on selective inhibitors of nuclear export (SINE), a class of compounds designed to interfere with the transport of tumor-suppressing proteins and other molecules in cancer cells.

Karyopharm’s leading product is selinexor, marketed in the United States as XPOVIO and in certain international markets as NEXPOVIO.